echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Another drug of Kexing Pharmaceuticals, which is deeply involved in the antiviral field, received IND acceptance

    Another drug of Kexing Pharmaceuticals, which is deeply involved in the antiviral field, received IND acceptance

    • Last Update: 2022-08-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the evening of August 14, Kexing Pharmaceuticals (68813SH) announced that the clinical trial application for "human interferon α2b spray" submitted by the company has been accepted by the State Food and Drug Administratio.


    On the evening of August 14, Kexing Pharmaceuticals (68813SH) announced that the clinical trial application for "human interferon α2b spray" submitted by the company has been accepted by the State Food and Drug Administratio.


    This is the third clinical trial application for antiviral drugs disclosed by Kexing Pharma on a rolling basis for three consecutive month.


    Kexing Pharmaceuticals (68813SH) is an innovative international biopharmaceutical enterprise mainly engaged in the research and development, production and sales of recombinant protein drugs and microecological preparation.


    It is understood that interferon can be described as a "sword" in the field of anti-viru.


    The human interferon α2b spray applied for this time is a class 2 improved new drug independently developed by Kexing Pharmaceutical.


    Kexing Pharmaceuticals stated that the advancement of the research and development of the company's human interferon α2b spray will help optimize the company's product structure, enrich the product pipeline, enhance the company's overall research and development capabilities, and enhance the company's long-term profitabilit.


    Another product application for clinical application! Kexing Pharmaceutical's long-term product research and development breakthrough
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.